An analysis to inventory all immune epitope data related to multiple sclerosis (MS) was performed using the Immune Epitope Database (IEDB). The analysis revealed that MS related data represent N 20% of all autoimmune data, and that studies of EAE predominate; only 22% of the references describe human data. To date, N 5800 unique peptides, analogs, mimotopes, and/or non-protein epitopes have been reported from 861 references, including data describing myelin-containing, as well as non-myelin antigens. This work provides a reference point for the scientific community of the universe of available data for MS-related adaptive immunity in the context of EAE and human disease.
Introduction
Multiple sclerosis (MS) is a progressive, debilitating neurological disorder characterized by central nervous system injury. The disease is largely regarded as autoimmune, primarily associated with genetic predisposition, though environmental factors have also been implicated (Lassman, 1983; Martin et al., 1992; Hafler et al., 2005; Sospedra & Martin, 2005) . The main pathological features of MS are inflammatory infiltrates, destruction of the myelin sheath and oligodendrocytes, axonal and neuronal damage as well as glial proliferation. Adaptive and immune mechanisms are at the core of disease pathogenesis. While much of the downstream immunopathology has been characterized, the initiating event for the development of MS has yet to be elucidated. Current treatment options for MS are based on immunomodulation/suppression, and include type I interferons, a peptidic mixture of 4 amino acids, glatiramer-acetate, a sphingosine 1 phosphate receptor agonist, fingolimod, fumaric acid, teriflunomide and monoclonal antibodies against VLA-4 and CD52 (Wagner, 2012) . Antigen-specific strategies have also been proposed and tested, and while this field has seen various setbacks (Hohlfeld & Wekerle, 2004) , promising data have recently been published for at least two approaches, including the administration of seven myelin peptides coupled to autologous PBMCs and skin patch application using a mixture of three myelin peptides (Lutterotti et al., 2013; Walczak et al., 2013) .
A great deal of what is now understood about MS was gained through studies using experimental autoimmune encephalomyelitis (EAE). EAE is the most common animal model used to simulate the human demyelination disease, MS, as it closely parallels key features of human disease, including inflammation, demyelination and gliosis (Rivers et al., 1933; Rao & Segal, 2012) . EAE models have been used extensively as surrogates for characterizing MS immunopathology and to test candidate neuroprotective and reparative strategies. These models include primarily mice and rats, but also include rabbits and non-human primates (Constantinescu et al., 2011) .
Despite its many merits, EAE differs from MS in several notable aspects. In most cases, EAE is experimentally induced (as the acronym implies) using antigens (peptides and proteins) along with bacteriallyderived adjuvants; spontaneous disease is achieved using transgenic mice models (Madsen et al., 1999; Quandt et al., 2012 
